Participants in a Phase 3 COVID-19 study who received the antiparasitic ivermectin fared about as well as those who got a placebo. Ivermectin recipients recovered in a median time of 12 days, while placebo recipients convalesced in 13 days on average.  The data from the ongoing ACTIV-6 study were published in JAMA. The study authors concluded that ivermectin did…